Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Requires hepatic bioactivation to an active thiol metabolite that irreversibly binds platelet P2Y12 receptors, inhibiting ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation.
Indications / reported uses
Prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischaemic stroke or established peripheral arterial disease
Acute coronary syndrome, including non-ST-elevation and ST-elevation myocardial infarction, in combination with aspirin under the applicable label
Prevention of stent thrombosis after percutaneous coronary intervention as part of dual antiplatelet therapy; duration is patient- and product-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Clopidogrel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clopidogrel Permitted Daily Exposure (PDE) report (the Clopidogrel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clopidogrel Occupational Exposure Limit (OEL) report (the Clopidogrel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.